Sage Journals: Discover world-class research

Abstract

We conducted a prospective study of a chromogenic LAL assay in 346 patients with sepsis syndrome, as defined by a modification of the Bone criteria, and 131 healthy volunteers at eight member centers of the Academic Medical College Consortium (AMCC). We identified patients with endotoxemia (> 0.40 EU/ml) by measuring LAL-reactive material in whole blood, extracted by the Tamura nitric acid method, with the chromogenic LAL (Pyrochrome®) assay. The mean result in sepsis patients with detectable endotoxemia (n = 241) was 1.07 ± 1.57 EU/ml, and the mean result in 131 volunteers was 0.151 ± 0.113 EU/ml, with 73% of the volunteers' results falling below the detectable limit. The average incidence of endotoxemia in sepsis patients was 33%, but varied 2.7-fold among the clinical centers (range 16-44%). Assay results were repeatable when samples tested frozen at the clinical sites were compared to results on frozen samples tested at Associates of Cape Cod, Inc. (ACC). Multiple samples were obtained from 40 patients at 18-24 h interval(s). Fourteen multidraw patients (35%) were endotoxemic at one or more draw(s) and eight of these patients had two or more draws with endotoxin levels > 1.0 EU/ml. The presence of sulfa drugs gave false positive results in two patient samples. A positive LAL test did not correlate with culture-proven bacterial infection and did not significantly correlate with mortality. There was a correlation (P = 0.014) between a patient having a positive LAL test and the presence of a fungal infection when mixed fungal and bacterial infections were included. There was no correlation with a positive LAL test when only a fungal infection was present (P = 0.425) or when only a fungal and a Gram-positive infection was present (P = 0.087).

Get full access to this article

View all access options for this article.

References

Levin J. , Buller H.R. , ten Cate J.W. , van Deventer S.J.H. , Sturk A. , eds. In: Bacterial Endotoxins - Pathophysiological Effects, Clinical Significance and Pharmacological Control. New York: Alan R. Liss, 1988.

Bone R.C. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993; 6: 57-68.

Dinarello C.A. , Cannon J.G. Cytokine measurements in septic shock. Ann Intern Med 1993; 119: 853-854.

Cannon J.G. , Tomkins R.G. , Gelfand J.A. et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84.

Yimin G. , Ezzell R.M. , Tompkins R.G. , Warren H.S. Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis 1994; 169: 95-104.

Hochstein H.D. , Fitzgerald E.A. , McMahon F.G. , Vargas R. Properties of US Standard Endotoxin (EC-5) in human male volunteers. J Endotoxin Res 1994; 1: 52-56.

Cross A.S. , Opal S.M. Endotoxin's role in Gram-negative bacterial infection. Curr Opin Infect Dis 1995; 8: 156-163.

Goldie A.S. , Fearon K.C.H. , Ross J.A. et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274: 172-177

Greenman R.L. , Schein R.M.H. , Martin M.A. et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266: 1097-1102.

10.

Ziegler E.J. , Fisher C.J. , Sprung C.L. et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991 ; 324: 429-436.

11.

Brun-Buisson C. , Doyon F. , Carlet J. et al. The French national registry of HA-1A (Centoxin) I septic shock. Arch Intern Med 1994; 154: 2484-2491.

12.

Novitsky T.J. Limulus amebocyte lysate (LAL) detection of endotoxin in human blood. j Endotoxin Res 1994; 1: 253-263.

13.

Hurley J.C. Concordance of endotoxemia with Gram-negative bacteremia in patients with Gram-negative sepsis: a meta-analysis. J Clin Microbiol 1994; 32: 2120-2127.

14.

Bone R.C. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions . Ann Intern Med 1991; 114: 332-333.

15.

Bates D.W. , Sands K. , Miller E. et al. Predicting bacteremia in patients with sepsis syndrome. 1997; Submitted for publication.

16.

Sands K.E. , Bates D.W. , Lanken P.N. et al. Epidemiology of sepsis syndrome in eight academic medical centers . 1997; Submitted for publication.

17.

Tamura H. , Tanaka S. , Obayashi T. , Yoshida M. , Kawai T. A new sensitive method for determining endotoxin in whole blood. Clin Chim Acta 1991; 200: 35-42.

18.

Tamura H. , Tanaka S. , Obayashi T. , Yoshida M. , Kawai T. A new sensitive microplate assay of plasma endotoxin. J Clin Lab Anal 1992; 6: 232-238.

19.

Saubolle M.A. , Jorgensen J.H. Use of the Limulus amebocyte lysate test as a cost-effective screen for Gram-negative agents of meningitis . Diagn Microbiol Infect Dis 1987; 7: 177-183.

20.

Nag N. , Ohno N. , Adachi Y. et al. Application of Limulus test (G pathway) for the detection of different conformers of (1→3)-β-D-glucans. Biol Pharm Bull 1993; 16: 822-828.

21.

Roslansky P.F. , Novitsky T.J. Sensitivity of Limulus amebocyte lysate (LAL) to LAL-reactive glucans. J Clin Microbiol 1991: 11: 2477-2483.

22.

Babineau T.J. , Hackford A. , Kenler A. et al. A phase II multicenter, double-blind, randomized placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129: 1204-1210.

23.

Danner R.L. , Elin RJ , Hosseini J.M. , Wesley R.A. , Reilly J.M. , Parillo J.E. Endotoxin in human septic shock. Chest 1991; 99: 169-175.

24.

Bone R.C. , Fisher C.J. , Clemmer T.P. et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.

25.

Wortel C.H. , von der Mohlen M.A.M. , van Deventer S.J.H. et al. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-lA) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 1992; 166: 1367-1374.

26.

Sasse K.C. , Nauenberg E. , Long A. , Anton B. , Tucker H.J. , Hu T-W. Long-term survival after intensive care unit admission with sepsis . Crit Care Med 23: 6: 1040-1047.

27.

Guidet B. , Barakett V. , Bassal T. , Petit J.C. , Offenstadt G. Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 1994; 106: 1194-1201.

28.

Levin J. , Poore T.E. , Zauber N.P. , Oser R.S. Detection of endotoxin in the blood of patients with sepsis due to Gram-negative bacteria. N Engl J Med 1970; 283: 1313-1316.

29.

van Deventer S.J.H. , Buller H.R. , ten Cate J.W. , Sturk A. , Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988; 8586: 605-608.

30.

Casey C. , Balk R. , Bone R. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993; 8: 771-778.

31.

Miyata T. , Todo S. , Selby R. et al. Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet 1989; 2: 189-191.

32.

Blanot S. , Gillon M.C. , Lopez L. , Ecoffey C. Circulating endotoxins and postreperfusion syndrome during orthotopic liver transplantation. Transplantation 1995 ; 60: 103-110.

Utilization of a chromogenic Limulus amebocyte lysate blood assay in a multi-center study of sepsis

Abstract

Get full access to this article

References